Robert Lefkowitz's team reports in Nature three compounds that block β-arrestins. In lab tests, the receptor that Ozempic targets stayed active longer. Researchers say this could lead to drugs with fewer side effects.
Recap by typeshit. Full story at SciTechDaily.
The once-daily pill blocks the IL-23 receptor and helped people with moderate to severe ulcerative colitis respond more often than placebo, a new study reports.
Bikman welcomes a new result but argues the likely cause is tirzepatide bringing insulin down rather than the drug slowing aging itself. His view, not a study claim.
Marchione makes the case for pairing GLP-1s with drugs that target amylin, the hormone released after meals that signals fullness to the brain.
Regen says the placebo group saw a 9% drop, while people on retatrutide also lost 31 lb on average and saw systolic blood pressure fall 14 points.
Pannu points to over $8B in upfront FGF21 deals and 500+ assets in development, and says the commercial and clinical split is arriving unusually early.
Analysts led by Yang Huang expect about 15% yearly growth, citing the large diabetes and obesity burden across the three countries.
Loading…